Alzheimer Disease Clinical Trial
Official title:
An Open-label Trial to Evaluate the Effects of BCG Immunization on Biomarkers of Inflammation/Immune Response and Alzheimer's Disease in Adults With Mild Cognitive Impairment and Mild-to-Moderate Dementia Due to Alzheimer's Disease
Verified date | February 2023 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
Status | Active, not recruiting |
Enrollment | 15 |
Est. completion date | October 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Individuals between the ages of 55-85; 2. MCI or moderate dementia due to AD as defined by the 2011 NIA-AA Workgroup recommendations; 3. MoCA = 8 at screening; 4. Global CDR between 0.5-2 (inclusive) at screening; 5. Amyloid and/or tau biomarkers indicative of AD pathology; 6. Education level, English language skills and literacy indicates subject will be able to complete all assessments; 7. Has a study partner who, in the investigator's judgement, has frequent, direct contact with the participant at least several days a week, can accompany the participant to all visits, and is also able to provide information to study investigator/staff; 8. Willing and able to complete all assessment and study procedures, including blood and lumbar punctures, and clinical assessments; 9. If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline; 10. Negative test results for HIV antibody and Tuberculosis (QuantiFERON) at screening; 11. No prior BCG exposure either through birth vaccinations (born in North American) or BCG bladder cancer treatment. Exclusion Criteria: 1. History of chronic infectious disease, such as HIV or untreated or active hepatitis; 2. History of tuberculosis, positive interferon-gamma release assay (IGRA, also known as the QuantiFERON-TB test), including a test with a high reactivity to mycobacteria of non-tuberculosis variety; 3. Prior BCG vaccination, positive T-spot tuberculosis test or a T-spot test showing significant Mycobacteria exposure; 4. A positive SARS-CoV-2 PCR result within 3 months of screening, or known close contact with a confirmed COVID-19 positive person or symptoms highly suspicious for COVID-19 (per CDC guidelines) within 1 month of screening, including fever, cough, shortness of breath, chills, muscle pain, new loss of taste or smell, vomiting or diarrhea, and/or sore throat, based on clinician's judgment; 5. History of treatment with metformin within the past one year; 6. Treatment with other investigational agents which, at the discretion of the investigator, interfere with safety and/or study outcomes; 7. Current treatment with immunosuppressants (calcineurin inhibitors, corticosteroids, or biological or cytotoxic immunosuppressants, or disease or condition likely to require high dose steroid or immunosuppressive therapy); 8. Other conditions or treatments associated with increased risk of infections or treatment with immunosuppressive medications for any reason; 9. Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs; 10. Current (as of time of study screening) or chronic use of antibiotics; 11. History of keloid formation; 12. Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example, HIV+ or taking immunosuppressive medications for any reason), or in a job (e.g. healthcare) in which the subject works with immunosuppressed populations; 13. Other/confounding neurological or psychiatric condition, unstable medical or psychiatric conditions, contraindications to BCG use and lab abnormalities or concurrent medication use posing risk for BCG or study procedures; 14. Laboratory abnormalities in B12, Folate, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction per clinician judgment; 15. Laboratory abnormalities in CBC, electrolytes, LFTs, BUN, Cr, total serum immunoglobulins, ESR, CRP, or urinalysis posing risk to treatment with BCG per clinician judgment; 16. Laboratory abnormalities in PT-INR, which would pose a risk to performing the lumbar puncture procedure; 17. Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit; 18. Females who are pregnant, lactating or of child-bearing potential; 19. If male with female partner(s) of childbearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol. 20. Administration of live vaccine within 30 days of screening visit or BCG immunizations 21. Administration of non-live vaccine within 14 days of screening visit or BCG immunizations 22. If participating in optional MRI: Existing contraindication to MRI per MGH Athinoula A. Martinos Center research guidelines |
Country | Name | City | State |
---|---|---|---|
United States | Alzheimer's Clinical and Translational Research Unit | Charlestown | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Steven E Arnold, MD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood biomarkers of pharmacodynamic response- cytokines | Change in concentration of circulating cytokines in blood from baseline | Day 364 | |
Primary | Blood biomarkers of pharmacodynamic response- cytokines | Change in concentration of circulating cytokines in blood from baseline | Day 84 | |
Primary | CSF biomarkers of pharmacodynamic response- cytokines | Change in concentration of circulating cytokines in CSF from baseline | Day 84 | |
Primary | CSF biomarkers of pharmacodynamic response- cytokines | Change in concentration of circulating cytokines in CSF from baseline | Day 364 | |
Primary | Blood biomarkers of AD pathology-ATN | Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline | Day 364 | |
Primary | CSF biomarkers of AD pathology-ATN | Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline | Day 364 | |
Primary | Blood biomarkers of AD pathology-ATN | Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline | Day 84 | |
Primary | CSF biomarkers of AD pathology-ATN | Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline | Day 84 | |
Primary | Cognitive Measures (RBANS) | Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score | Day 84 | |
Primary | Cognitive Measures (RBANS) | Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score | Day 364 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |